Abstract
Photodynamic therapy (PDT) has represented an important treatment modality in many ocular disorders for more than a decade. The introduction of verteporfin-PDT to the treatment of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy has rescued millions of patients from vision loss and blindness around the world. The most well-known vascular tumors in the eye treated with PDT include retinal capillary hemangioma, choroidal hemangioma, retinal vasoproliferative tumor or Wyburn-Mason syndrome. The discovery of the role of vascular endothelial cell growth factor in age-related macular degeneration and the revolution of its treatment by anti-vascular endothelial cell growth factor agents reduced the need for PDT in age-related macular degeneration; however, the use of PDT in the treatment of PCV is dramatically increasing. Furthermore, clinical results obtained with PDT, in combination with angiogenesis inhibitors, vascular disrupting agents, or/and anti-inflammatory compounds as adjuvant therapies, may well keep PDT as one the main treatment options. This review summarizes the present role and future possible improvements of ocular PDT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Analytical & Bioanalytical Techniques
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
